The value of research collaborations and consortia in rare cancers

Area of Science:

• Oncology
• Cancer Research
• Public Health

Background:

• Rare cancers, defined as <6 cases per 100,000 people annually, constitute ~20% of all cancer diagnoses.
• These cancers are linked to inferior survival outcomes compared to common tumors.
• Contributing factors include diagnostic delays, suboptimal treatments, and limited clinical trial participation.

Purpose of the Study:

• To explore strategies for addressing the challenges in rare cancer research and management.
• To propose the integration of research consortia with multidisciplinary expert reference networks.

Main Methods:

• Review of current challenges in rare cancer research.
• Proposal for a collaborative model integrating research consortia and reference networks.

Main Results:

• Identification of key barriers in rare cancer care: delayed diagnosis, inadequate treatment, and lack of clinical trials.
• A framework for integrating research consortia and reference networks is presented.

Conclusions:

• Integrating research consortia with expert reference networks offers a viable solution to improve rare cancer outcomes.
• This integrated approach can enhance diagnosis, treatment, and clinical trial opportunities for rare tumor patients.